Compare Regeneron Pharmaceuticals Inc (REGN) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Unity Software Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Unity Software Inc trades at $29.19 (market cap $13.04B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.4× Unity Software Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals.
| REGN | U | |
|---|---|---|
Market Cap | $70.79B | $13.04B |
Sector | Health | Technology |
52-Week High | $812.27 | $49.47 |
52-Week Low | $545.46 | $17.13 |
Enterprise Value | $64.74B | $13.13B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Unity Software (U) trades at $29.87, up 3.04% today, showing bullish technical momentum above key support levels. The company maintains strong revenue of $1.85B with improving gross margins at 62.79%, though net losses persist at -$402.77M. Recent Unity 7 platform announcements and AI integration focus signal strategic growth initiatives. Analyst consensus remains strongly bullish with 69% buy ratings and $36.50 price target, representing 22% upside potential from current levels.
Unity presents a growth opportunity with improving financial trends and strong institutional support, but faces execution risks in profitability turnaround. The stock's elevated valuation multiples (P/S 6.61, EV/EBITDA 134.62) require sustained revenue growth justification. Near-term catalyst includes Q2 2026 earnings on August 5, where analysts expect EPS of $0.24 after recent misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
